Equities Analysts Set Expectations for CAPR FY2025 Earnings
Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Capricor Therapeutics in a research ...
Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) Target Price at $34.50
Shares of Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) have received an average rating of “Buy” from the six ...
Capricor Therapeutics (NASDAQ:CAPR) delivers shareholders fantastic 54% CAGR over 5 years, surging 12% in the last week alone
Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) shareholders might understandably be very concerned that the share ...
Kymera Therapeutics: Balancing Pipeline Opportunities with Uncertainties in KT-621 Development
Kymera Therapeutics (KYMR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Vikram ...
Kymera Therapeutics: Strategic Advancements and Strong Financials Bolster Buy Rating by Analyst
Leerink Partners analyst Faisal Khurshid has reiterated their bullish stance on KYMR stock, giving a Buy rating yesterday.Stay Ahead of the ...